Format
Sort by
Items per page

Send to

Choose Destination

Best matches for HEMATOPOIETIC CELL TRANSPLANTATION:

Long-term complications after hematopoietic cell transplantation. Majhail NS et al. Hematol Oncol Stem Cell Ther. (2017)

Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation. Maffini E et al. Biol Blood Marrow Transplant. (2017)

Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Passweg JR et al. Bone Marrow Transplant. (2016)

Search results

Items: 1 to 20 of 63040

1.

Follistatin and Soluble Endoglin Predict 1-year Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplant.

Newell LF, DeFor TE, Cutler C, Verneris MR, Blazar BR, Miller JS, Antin JH, Howard A, Wu J, MacMillan ML, Panoskaltsis-Mortari A, Weisdorf DJ, Holtan SG.

Biol Blood Marrow Transplant. 2019 Nov 9. pii: S1083-8791(19)30746-3. doi: 10.1016/j.bbmt.2019.11.006. [Epub ahead of print]

PMID:
31715306
2.

Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation.

Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, Tanaka M, Yuju O, Eto T, Ozawa Y, Takada S, Takanashi M, Kato K, Kanda Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation.

Biol Blood Marrow Transplant. 2019 Nov 9. pii: S1083-8791(19)30741-4. doi: 10.1016/j.bbmt.2019.11.001. [Epub ahead of print]

PMID:
31715305
3.

Impact of γδ T cells on clinical outcome of hematopoietic stem cell transplantation: systematic review and meta-analysis.

Arruda LCM, Gaballa A, Uhlin M.

Blood Adv. 2019 Nov 12;3(21):3436-3448. doi: 10.1182/bloodadvances.2019000682.

PMID:
31714966
4.

Microbiota modification in hematology: still at the bench or ready for the bedside?

Severyn CJ, Brewster R, Andermann TM.

Blood Adv. 2019 Nov 12;3(21):3461-3472. doi: 10.1182/bloodadvances.2019000365.

PMID:
31714965
5.

Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia.

Huang QS, Wang JZ, Qin YZ, Zeng QZ, Jiang Q, Jiang H, Lu J, Liu HX, Liu Y, Wang JB, Su L, Zhang HY, Li ZL, Gao SJ, Huang B, Liu YY, Liu YR, Xu LP, Huang XJ, Zhang XH.

Blood Adv. 2019 Nov 12;3(21):3406-3418. doi: 10.1182/bloodadvances.2019000564.

PMID:
31714962
6.

More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling.

Bader P, Salzmann-Manrique E, Balduzzi A, Dalle JH, Woolfrey AE, Bar M, Verneris MR, Borowitz MJ, Shah NN, Gossai N, Shaw PJ, Chen AR, Schultz KR, Kreyenberg H, Di Maio L, Cazzaniga G, Eckert C, van der Velden VHJ, Sutton R, Lankester A, Peters C, Klingebiel TE, Willasch AM, Grupp SA, Pulsipher MA.

Blood Adv. 2019 Nov 12;3(21):3393-3405. doi: 10.1182/bloodadvances.2019000449.

PMID:
31714961
7.

Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.

Iliopoulou BP, Hsu K, Pérez-Cruz M, Tang SW, Pang WW, Erkers T, Kambham N, Freeman GJ, Dekruyff RH, Meyer EH.

Blood Adv. 2019 Nov 12;3(21):3419-3431. doi: 10.1182/bloodadvances.2019000286.

PMID:
31714958
8.

Prognostic significance of low pre-transplant skeletal muscle mass on survival outcomes in patients undergoing hematopoietic stem cell transplantation.

Sakatoku K, Ito A, Tajima K, Yamaguchi K, Kuno M, Aoki N, Tanaka T, Kurosawa S, Inamoto Y, Kim SW, Fukuda T.

Int J Hematol. 2019 Nov 12. doi: 10.1007/s12185-019-02773-0. [Epub ahead of print]

PMID:
31713713
9.

Outcomes of allogeneic stem cell transplantation for DLBCL: a multi-center study from the Kyoto Stem Cell Transplantation Group.

Izumi K, Kanda J, Nishikori M, Arai Y, Ishikawa T, Yoshioka S, Ueda Y, Maeda T, Yonezawa A, Anzai N, Moriguchi T, Imada K, Akasaka T, Nohgawa M, Itoh M, Aiba A, Tsunemine H, Watanabe M, Kondo T, Takaori-Kondo A.

Ann Hematol. 2019 Nov 12. doi: 10.1007/s00277-019-03835-3. [Epub ahead of print]

PMID:
31713653
10.

Oral calcitriol in hematopoietic recovery and survival after autologous stem cell transplantation: a randomized clinical trial.

Raoufinejad K, Shamshiri AR, Pezeshki S, Chahardouli B, Hadjibabaie M, Jahangard-Rafsanjani Z, Gholami K, Rajabi M, Vaezi M.

Daru. 2019 Nov 11. doi: 10.1007/s40199-019-00306-y. [Epub ahead of print]

PMID:
31713184
11.

Novel DDX41 variants in Thai patients with myeloid neoplasms.

Polprasert C, Takeda J, Niparuck P, Rattanathammethee T, Pirunsarn A, Suksusut A, Kobbuaklee S, Wudhikarn K, Lawasut P, Kongkiatkamon S, Chuncharunee S, Songserm K, Phowthongkum P, Bunworasate U, Nannya Y, Yoshida K, Makishima H, Ogawa S, Rojnuckarin P.

Int J Hematol. 2019 Nov 11. doi: 10.1007/s12185-019-02770-3. [Epub ahead of print]

PMID:
31713024
12.

Effect of the severity of acute graft-versus-host disease on physical function after allogeneic hematopoietic stem cell transplantation.

Hamada R, Kondo T, Murao M, Miyasaka J, Yoshida M, Nankaku M, Kanda J, Takaori-Kondo A, Ikeguchi R, Matsuda S.

Support Care Cancer. 2019 Nov 12. doi: 10.1007/s00520-019-05124-1. [Epub ahead of print]

PMID:
31712955
13.

Cytomegalovirus in Allogeneic Hematopoietic Transplantation: Impact on Costs and Clinical Outcomes Utilizing a Preemptive Strategy.

Saullo JL, Li Y, Messina JA, Thompson J, Dalton T, Giri VK, Reed SD, Miller R, Horwitz ME, Alexander BD, Sung AD.

Biol Blood Marrow Transplant. 2019 Nov 8. pii: S1083-8791(19)30745-1. doi: 10.1016/j.bbmt.2019.11.005. [Epub ahead of print]

PMID:
31712193
14.

The value of Torque Teno Virus (TTV) as a marker for the degree of immunosuppression in adult patients after hematopoietic stem cell transplantation (HSCT).

Schmitz J, Kobbe G, Kondakci M, Schuler E, Magorsch M, Adams O.

Biol Blood Marrow Transplant. 2019 Nov 8. pii: S1083-8791(19)30742-6. doi: 10.1016/j.bbmt.2019.11.002. [Epub ahead of print]

PMID:
31712192
15.

Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM.

Merz LE, Perissinotti AJ, Marini BL, Burke PW, Crouch A, Erba HP, Bixby D.

Clin Lymphoma Myeloma Leuk. 2019 Sep 28. pii: S2152-2650(19)32002-6. doi: 10.1016/j.clml.2019.09.615. [Epub ahead of print]

PMID:
31711889
17.

HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.

He Z, Zhang S, Ma D, Fang Q, Yang L, Shen S, Chen Y, Ren L, Wang J.

J Transl Med. 2019 Nov 11;17(1):366. doi: 10.1186/s12967-019-2115-9.

PMID:
31711520
18.

Myelofibrosis: best practices, controversies and 2019 update.

Cruz NM, Gergis U, Silver RT.

Expert Rev Hematol. 2019 Nov 8. doi: 10.1080/17474086.2020.1691519. [Epub ahead of print]

PMID:
31709843
19.

Microfluidic Cell Trap Arrays for Single Hematopoietic Stem/Progenitor Cell Behavior Analysis.

Han X, Ma Y, Zhang K, Zhang P, Shao N, Qin L.

Proteomics. 2019 Nov 11:e1900223. doi: 10.1002/pmic.201900223. [Epub ahead of print]

PMID:
31709756
20.

Allogeneic HSCT in Adolescents and Young Adults With Primary Immunodeficiencies.

Morris EC, Albert MH.

Front Pediatr. 2019 Oct 24;7:437. doi: 10.3389/fped.2019.00437. eCollection 2019. Review.

Supplemental Content

Loading ...
Support Center